集落刺激因子治疗终末期酒精性肝病的临床对照研究

摘要/Abstract

摘要： 目的评价重组人粒细胞集落刺激因子(G-CSF)治疗终末期酒精性肝病患者疗效和安全性。方法将36例终末期酒精性肝病患者随机分为2组,试验组18例,对照组18例。对照组给予基础治疗,试验组在基础治疗的同时给予G-CSF治疗,G-CSF剂量和用法为:5 μg/kg,1次/12 h,皮下注射,连续7 d。结果试验组对比对照组MDF及MELD评分在1、2、3个月均有显著降低(P<0.05)。试验组相对对照组CD34⁺细胞计数下降显著(0.46±0.58对0.15±0.2,P=0.020)。90 d内试验组生存率显著高于对照组(χ²=14.995,P=0.000)。治疗期间无严重不良反应。结论 G-CSF能够提高终末期酒精性肝病患者的生存率,并且安全性较高。

关键词: 粒细胞集落刺激因子, 酒精性肝病, 肝衰竭, 临床研究

周培, 于淙, 渠淑云. 集落刺激因子治疗终末期酒精性肝病的临床对照研究[J]. 肝脏, 2020, 25(5): 521-524.

参考文献

[1] 中华医学会肝病学分会脂肪肝和酒精性肝病学组,中国医师协会脂肪性肝病专家委员会. 酒精性肝病防治指南(2018更新版). 中华肝脏病杂志,2018, 26:188-194.
[2] Yannaki E , Athanasiou E , Xagorari A et al. G-CSF-primed hematopoietic stem cells or G-CSF per se accelerate recovery and improve survival after liver injury, predominantly by promoting endogenous repair programs . Exp Hematol,2005,33: 108-119.
[3] Simonetto DA, Shah VH, Kamath PS.Improving survival in ACLF: growing evidence for use of G-CSF. Hepatol Int, 2017,11:473-475.
[4] Spahr L, Chalandon Y, Terraz S et al.Autologous bone marrow mononuclear cell transplantation in patients with decompensated alcoholic liver disease:a randomized controlled trial.PLoSOne, 2013,8:e53719
[5] Thursz MR, Richardson P, Allison M et al. Prednisolone or pentoxifylline for alcoholic hepatitis. N Engl J Med, 2015,372:1619-1628.
[6] Singh S, Osna NA, Kharbanda KK.Treatment options for alcoholic and non-alcoholic fatty liver disease: a review. World J Gastroenterol, 2017,23:6549-6570.
[7] Garg V , Garg H , Khan A et al. Granulocyte-colony stimulating factor mobilizes CD34⁺ cells and improves survival of patients with acute-on-chronic liver failure.Gastroenterology, 2012,142:505-512.
[8] Godfrey EL, Stribling R, Rana A.Liver transplantation for alcoholic liver disease: an Update. Clin Liver Dis, 2019,23:127-139.
[9] Gaia S, Smedile A, Omedè P et al.Feasibility and safety of G-CSF administration to induce bone marrow-derived cells mobilization in patients with end stage liver disease. J Hepatol, 2006,45:13-19.
[10] Cho Y, Park YS, Kim HY et al,efficacy of granulocyte colony stimulating factor in patients with severe alcoholic hepatitis with partial or null response tosteroid (GRACIAH trial): study protocol for a randomized controlled trial.. Trials, 2018,22,19:696.
[11] Di Campli C, Zocco MA, Saulnier N et al,Safety and efficacy profile of G-CSF therapy in patients with acute on chronic liver failure. Dig Liver Dis, 2007,39:1071-1076.
[12] Duan XZ, Liu FF, Tong JJ et al. Granulocyte-colony stimulating factor therapy improves survival in patients with hepatitis B virus-associated acute-on-chronic liver failure. World J Gastroenterol, 2013,21,19:1104-1110.
[13] 杨昊臻,郑楠楠,胡瑾华. 重组人粒细胞集落刺激因子的免疫调节作用及其在肝衰竭中的应用.中华肝脏病杂志,2013, 21:718-720.
[14] Spahr L , Chalandan Y , Terraz S et al. Autologous bone marrow mononuclear cell transplantation in patients with decompensated alcoholic liver disease: a randomized controlled trial. PLoS One,2013,8: e53719.
[15] 马玉杰, 梁辉. 重组人G-CSF治疗不同白细胞减少症的疗效与机制. 上海交通大学学报(医学版),2009, 29: 1081-1084.
[16] 王亚东,马路园,季茹,等.粒细胞集落刺激因子在肝衰竭治疗中的作用机制及其临床应用研究进展. 中华内科杂志, 2017, 56:954-957.